Un-audited Results for the Quarter and nine months ended 31.12.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd (BSE: 524636), a subsidiary of Virupaksha Organics Ltd, reported unaudited results for the quarter and nine months ended December 31, 2025. Net loss for Q3 FY26 stood at Rs 543.30 lakhs, wider than Rs 493.09 lakhs in the same quarter last year. Loss before tax for the quarter rose to Rs 632.65 lakhs from Rs 496.18 lakhs, a ~27% jump, while revenue was nearly flat at Rs 3,393 lakhs versus Rs 3,321 lakhs (up just ~2%). For the nine-month period, the company posted a net loss of Rs 1,191.02 lakhs on revenue of Rs 6,338 lakhs, compared to a loss of Rs 1,145.80 lakhs on revenue of Rs 5,983 lakhs a year ago. The statutory auditor issued a clean (unmodified) limited review report, though management flagged pending MSME creditor identification and incomplete bill-by-bill reconciliation. The Board also reconstituted its Internal Complaints Committee under the POSH Act.
The company remains loss-making with widening quarterly losses despite roughly flat revenue, indicating continued margin pressure and limited operating leverage. This is negative for shareholders and suggests no near-term turnaround in profitability.